Sort
40,608 grants matching “prostate cancer”
Characterizing Genetic Susceptibility to Breast and Prostate Cancer: The BPC3.
$312,578Susan M Gapstur · American Cancer Society, Inc. · U01 · FY2010 · CA
Nanoparticle-mediated treatment for bone metastasis
$312,562Vinod D Labhasetwar · Cleveland Clinic Lerner Com-Cwru · R01 · FY2017 · CA
Nanoparticle-mediated treatment for bone metastasis
$312,562Vinod D Labhasetwar · Cleveland Clinic Lerner Com-Cwru · R01 · FY2016 · CA
Nanoparticle-mediated treatment for bone metastasis
$312,562Vinod D Labhasetwar · Cleveland Clinic Lerner Com-Cwru · R01 · FY2018 · CA
Structure, dynamics and function of RNA binding proteins
$312,550Francesca Massi · Univ Of Massachusetts Med Sch Worcester · R01 · FY2012 · GM
Structure, dynamics and function of RNA binding proteins
$312,550Francesca Massi · Univ Of Massachusetts Med Sch Worcester · R01 · FY2014 · GM
Structure, dynamics and function of RNA binding proteins
$312,550Francesca Massi · Univ Of Massachusetts Med Sch Worcester · R01 · FY2015 · GM
Structure, dynamics and function of RNA binding proteins
$312,550Francesca Massi · Univ Of Massachusetts Med Sch Worcester · R01 · FY2011 · GM
Engineered HGF-NK1 antagonists for Met-targeted cancer imaging and therapy
$312,514Jennifer R Cochran · Stanford University · R01 · FY2014 · CA
4D IMRT: Stereotactic body radiotherapy for lung cancer
$312,504Paul J Keall · Stanford University · R01 · FY2010 · CA
Molecular Imaging of Chemokine Receptor Signaling
$312,499Gary D Luker · University Of Michigan At Ann Arbor · R01 · FY2009 · CA
Anticarcinogenic Effect of ITCs Against Prostate Cancer
$312,472Shivendra Singh · University Of Pittsburgh At Pittsburgh · R01 · FY2007 · CA
The Six1/Eya Transcriptional complex as a mediator of lymphangiogenesis and lymph
$312,416Heide L Ford · University Of Colorado Denver · R01 · FY2015 · CA
Dose-response relationships between circulating and intraprostatic androgens in m
$312,399Stephanie T Page · University Of Washington · R01 · FY2012 · AG
Local Radiation as an Adjuvant for Immunotherapy
$312,389Sandra Demaria · New York University School Of Medicine · R01 · FY2011 · CA
OV Therapy Induced Changes in Tumor Secretome and Their Impact on Therapy
$312,375Balveen Kaur · Ohio State University · R01 · FY2012 · NS
OV Therapy Induced Changes in Tumor Secretome and Their Impact on Therapy
$312,375Balveen Kaur · Ohio State University · R01 · FY2011 · NS
DNA Damage-Response Defects in Prostate Cancer Risk
$312,374Wanguo Liu · Lsu Health Sciences Center · R01 · FY2008 · CA
Identification of Methylated Genes in Chronic Lymphocytic Leukemia
$312,371Christoph Plass · Ohio State University · P01 · FY2009 · CA
Development of Hsp90 inhibitors for the treatment of cancer
$312,346Brian S J Blagg · University Of Kansas Lawrence · R01 · FY2015 · CA
Role of the tumor suppressor KLF6 in prostate cancer
$312,340John A Martignetti · Icahn School Of Medicine At Mount Sinai · R01 · FY2011 · CA
Steroid Metabolism in Castration-Resistant Prostate Cancer
$312,309Peter S Nelson · Beth Israel Deaconess Medical Center · P01 · FY2016 · CA
An inevitable mechanism of resistance to androgen-directed therapy
$312,288Yan Dong · Tulane University Of Louisiana · R01 · FY2015 · CA
The role of IL-17 in prostate cancer
$312,288Zongbing You · Tulane University Of Louisiana · R01 · FY2013 · CA
Enhancement of BB2r-Targeted Radiotherapy for Prostate Cancer Utilizing Hypoxia-S
$312,288Jered C Garrison · University Of Nebraska Medical Center · R01 · FY2017 · CA